“双十定律”所描绘的“十年研发、十亿美金”的高门槛，是每一家创新药企必须面对的行业现实，诺诚健华亦不例外。面对过去三年累计超22亿元、占营收九成以上的高强度研发投入，企业如何保障发展的可持续性？诺诚健华的实践，揭示了一条以资本市场为前驱动力、以商业化落地为价值转化器的发展路径。回溯其发展历程，从登陆港交所到成功在科创板实现“A+H”两地上市，累计超50亿元的资本活水，为企业的创新研发提供了关键支撑...
Source Link“双十定律”所描绘的“十年研发、十亿美金”的高门槛，是每一家创新药企必须面对的行业现实，诺诚健华亦不例外。面对过去三年累计超22亿元、占营收九成以上的高强度研发投入，企业如何保障发展的可持续性？诺诚健华的实践，揭示了一条以资本市场为前驱动力、以商业化落地为价值转化器的发展路径。回溯其发展历程，从登陆港交所到成功在科创板实现“A+H”两地上市，累计超50亿元的资本活水，为企业的创新研发提供了关键支撑...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.